Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$83.47 USD
+1.20 (1.46%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $83.47 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Company Summary
India-based Dr. Reddy’s Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy’s operates through three segments:
• Global Generics – This segment consists of unbranded prescription drugs along with over-the-counter (OTC) drugs. It includes the operations of the company’s biologics business. The segment accounted for about 87% of the company’s total revenues generated in fiscal 2024.
• ...
Company Summary
India-based Dr. Reddy’s Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy’s operates through three segments:
• Global Generics – This segment consists of unbranded prescription drugs along with over-the-counter (OTC) drugs. It includes the operations of the company’s biologics business. The segment accounted for about 87% of the company’s total revenues generated in fiscal 2024.
• Pharmaceutical Services & Active Ingredients (PSAI) – This segment is composed of active pharmaceutical ingredients (API) and custom pharmaceutical services. The segment accounted for about 12% of the company’s total revenues generated in fiscal 2024.
• Others – This segment involves the new chemical entities, the differentiated formulations business and a dermatology specialty business. The segment accounted for about 1% of the company’s total revenues generated in fiscal 2024.
Dr. Reddy’s reported fiscal 2024 (ending Mar 31, 2024) revenues of $3.35 billion, up 14% from fiscal 2023. Global Generics contributed 87%, PSAI contributed 12%, and Proprietary Products and Others contributed 1% to total revenues in fiscal 2024.
The company has strategic partnerships with several pharma companies to market selected products across emerging markets outside India. Last year, Dr. Reddy’s divested certain non-core brands of the company in the dermatology segments to Eris Lifesciences Limited in India as part of a strategic decision to focus on strengthening its core business.
Dr. Reddy’s enjoys a strong position in the generics market. As of Jun 30, 2024, cumulatively, 80 generic filings were pending approval from the FDA (75 abbreviated new drug applications [ANDAs] and five new drug applications). Of these 75 ANDAs, 45 are Para IVs.
General Information
Dr Reddy's Laboratories Ltd
8-2-337 ROAD NO.3 BANJARA HILLS
HYDERABAD, K7 500-034
Phone: 91-40-4900-2900
Fax: 91-40-4900-2999
Email: richaperiwal@drreddys.com
Industry | Medical - Generic Drugs |
Sector | Medical |
Fiscal Year End | March |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 10/25/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.99 |
Current Year EPS Consensus Estimate | 4.11 |
Estimated Long-Term EPS Growth Rate | 11.10 |
Exp Earnings Date | 10/25/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 82.27 |
52 Week High | 84.46 |
52 Week Low | 63.72 |
Beta | 0.55 |
20 Day Moving Average | 191,224.30 |
Target Price Consensus | 82.17 |
4 Week | 0.32 |
12 Week | 16.97 |
YTD | 19.96 |
4 Week | -5.04 |
12 Week | 10.73 |
YTD | 1.30 |
Shares Outstanding (millions) | 166.92 |
Market Capitalization (millions) | 13,933.04 |
Short Ratio | NA |
Last Split Date | 9/7/2006 |
Dividend Yield | 0.48% |
Annual Dividend | $0.40 |
Payout Ratio | 0.10 |
Change in Payout Ratio | -0.01 |
Last Dividend Payout / Amount | 7/30/2024 / $0.40 |
Fundamental Ratios
P/E (F1) | 20.31 |
Trailing 12 Months | 20.87 |
PEG Ratio | 1.84 |
vs. Previous Year | -2.91% |
vs. Previous Quarter | 6.38% |
vs. Previous Year | 12.14% |
vs. Previous Quarter | 8.21% |
Price/Book | 3.94 |
Price/Cash Flow | 16.47 |
Price / Sales | 4.02 |
6/30/24 | 20.32 |
3/31/24 | 21.32 |
12/31/23 | 20.97 |
6/30/24 | 14.62 |
3/31/24 | 15.47 |
12/31/23 | 15.19 |
6/30/24 | 2.55 |
3/31/24 | 2.58 |
12/31/23 | 2.55 |
6/30/24 | 1.90 |
3/31/24 | 1.92 |
12/31/23 | 1.90 |
6/30/24 | 19.28 |
3/31/24 | 19.97 |
12/31/23 | 19.26 |
6/30/24 | 19.28 |
3/31/24 | 19.97 |
12/31/23 | 19.26 |
6/30/24 | 24.88 |
3/31/24 | 25.73 |
12/31/23 | 25.04 |
6/30/24 | 21.19 |
3/31/24 | 20.17 |
12/31/23 | 19.30 |
6/30/24 | 1.89 |
3/31/24 | 1.97 |
12/31/23 | 2.04 |
6/30/24 | 0.02 |
3/31/24 | 0.02 |
12/31/23 | 0.02 |
6/30/24 | 2.08 |
3/31/24 | 2.09 |
12/31/23 | 2.25 |